Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol for prevention of stroke and improvement of cerebral perfusion in asymptomatic moyamoya disease
KCT0011488Phase 2Not yet recruiting
- Sponsor
- Korea United Pharm Inc.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cilostazol in Moyamoya disease, sponsored by Korea United Pharm Inc.. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
cilostazol
03
Conditions
Moyamoya disease
Beyond the preview
Go deeper on KCT0011488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011488.